Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Bid for Orchid Cellmark for Seventh Time

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today announced it has extended its $85.4 million bid for Orchid Cellmark to 5 p.m. EDT Nov. 4.

It is the seventh time the proposed deal, in which LabCorp will pay $2.80 for each share of Orchid stock, has been extended. It previously had been extended to Oct. 7.

LabCorp received a request from the US Federal Trade Commission in May for additional information about the purchase and continues to cooperate with the agency's request.

The depositary for the tender offer has told LabCorp that as of 5 p.m. Oct. 7 EDT, shareholders of Orchid had validly tendered and not withdrawn 26,224,903 shares of the company's common stock, including 61,080 shares tendered through notices of guaranteed delivery.

The shares tendered represent about 87.4 percent of all outstanding shares of Orchid, and about 87.2 percent excluding the shares tendered by notices of guaranteed delivery.

On a fully diluted basis, the tendered shares represent about 80.2 percent of all outstanding shares and 80 percent excluding shares tendered by notices of guaranteed delivery.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.